






Supplementary Fig. S1. Rose plots illustrating the monthly distribution of positive LIAs for the 18 autoantibodies. Data are presented as absolute numbers of positive results, color-coded by year, as presented in the legend. The circular mean is indicated by the red line on the plots.




Supplementary Fig. S1. Rose plots illustrating the monthly distribution of positive LIAs for the 18 autoantibodies. Data are presented as absolute numbers of positive results, color-coded by year, as presented in the legend. The circular mean is indicated by the red line on the plots.

Supplementary Table S1: Yearly distribution of tests performed with EUROLINE Autoimmune Inflammatory Myopathies (16 Ag & 18 Ag) line immunoassays (LIA) during the years 2017-2025.


Line immunoassay (LIA) type		
Year	EUROLINE Autoimmune Inflammatory Myopathies 16 Ag (IgG)	EUROLINE Autoimmune Inflammatory Myopathies 18 Ag (IgG)
2017	97	0
2018	137	0
2019	256	0
2020	194	0
2021	297	6
2022	31	214
2023	0	302
2024	0	289
2025	0	73




Supplementary Fig. S2. Rose plots illustrating the monthly distribution of positive LIAs for the 18 autoantibodies. Data are presented as ratios of medium-positive tests ($11 \leq x \leq 25$) per total tests, color-coded by year as presented in the legend. The circular mean is indicated by the red line on the plots.




Supplementary Fig. S2. Rose plots illustrating the monthly distribution of positive LIAs for the 18 autoantibodies. Data are presented as ratios of medium-positive tests ($11 \leq x \leq 25$) per total tests, color-coded by year as presented in the legend. The circular mean is indicated by the red line on the plots.




Supplementary Fig. S3. Rose plots illustrating the monthly distribution of positive LIAs for the 18 autoantibodies. Data are presented as ratios of strong-positive tests ($x \geq 26$) per total tests, color-coded by year as presented in the legend. The circular mean is indicated by the red line on the plots.



Supplementary Fig. S3. Rose plots illustrating the monthly distribution of positive LIAs for the 18 autoantibodies. Data are presented as ratios of strong-positive tests ($x \geq 26$) per total tests, color-coded by year as presented in the legend. The circular mean is indicated by the red line on the plots.



Supplementary Fig. S4. Bar plots illustrating a comparative analysis of myositis autoantibodies' positive rates before COVID-19 (2017-2019) and during COVID-19 (2020-2024). A predefined autoantibody signal intensity value ≥ 11 threshold is categorised as Positive. Statistical analysis was performed for positive autoantibodies between 2017-2019 and 2020-2024 periods using the χ^2 test.



Supplementary Fig. S5. Bar plots illustrating a comparative analysis of myositis autoantibodies' Positive and Strongly Positive rates before COVID-19 (2017-2019) and during COVID-19 (2020-2024). Predefined thresholds of signal intensity of autoantibodies are: (a) 11-25: medium-positive titres, (b) ≥ 26 : strong positive titres. Statistical analysis was performed separately for both medium-positive and strong-positive autoantibodies between the 2017-2019 and 2020-2024 periods using the χ^2 test.

Supplementary Table S2: Myositis autoantibody seasonality: findings from Greek and international cohorts.

Myositis autoantibody	Seasonal peak	Population/region Studied	Source
Anti-HMGCR	Spring-summer	Greek cohort	Current study
Anti-MDA5	Fall-Winter	Italian cohort	Palterer <i>et al.</i> , 2025
Anti-MDA5	October-March	Japan cohort	Nishina <i>et al.</i> , 2020
Anti-MDA5	October-December	Chinese cohort	So <i>et al.</i> , 2022
Anti-Mi2b	Fall-Winter	Italian cohort	Palterer <i>et al.</i> , 2025
Anti-OJ	Fall-Winter (borderline)	Greek cohort	Current study
Antisynthetase antibodies	March-April	U.S. cohort (non-black male)	Sarkar <i>et al.</i> , 2005
Anti-Jo-1	April	U.S. cohort	Leff <i>et al.</i> , 1991
Anti-SRP	November	U.S. cohort	Leff <i>et al.</i> , 1991
Anti-PM-Sc1100	Fall-Winter	Greek cohort	Current study
Anti-PM-Sc175	Fall-Winter	Greek cohort	Current study
Anti-PM-Sc175	Fall-Winter	Italian cohort	Palterer <i>et al.</i> , 2025
Anti-TIF-1 γ	Fall-Winter (borderline)	Greek cohort	Current study
Anti-TIF-1 γ	Fall-Winter	Italian cohort	Palterer <i>et al.</i> , 2025